PolyGene

Explore the latest insights on PolyGene and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of PolyGene’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Hengrui's HRS-4139 Wins NMPA Clinical Trial Approval – Class 1 First‑in‑Target Candidate Targets Moderate‑to‑Severe Plaque Psoriasis
CompanyDrug

Hengrui’s HRS-4139 Wins NMPA Clinical Trial Approval – Class 1 First‑in‑Target Candidate Targets Moderate‑to‑Severe Plaque Psoriasis

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its drug HRS‑4139 has been approved by China's National Medical Products Administration (NMPA) for clinical trials targeting moderate‑to‑severe plaque…

IASO Bio's In Vivo CAR‑T IASO208 Receives FDA Implicit IND Approval – Off‑the‑Shelf CD20 Therapy Targets Relapsed/Refractory B‑NHL

IASO Bio’s In Vivo CAR‑T IASO208 Receives FDA Implicit IND Approval – Off‑the‑Shelf CD20 Therapy Targets Relapsed/Refractory B‑NHL

Chia Tai Tianqing's Dual Category 1 Biologics Applications Accepted by NMPA – TQB2102 HER2‑Low ADC and TQH2722 IL‑4Rα Antibody Advance Toward Approval

Chia Tai Tianqing’s Dual Category 1 Biologics Applications Accepted by NMPA – TQB2102 HER2‑Low ADC and TQH2722 IL‑4Rα Antibody Advance Toward Approval

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Santo Therapeutics and PolyGene Sign Strategic Partnership – Joint Gene Therapy Delivery Push Targets NF1 Skin Disease
CompanyDeals

Santo Therapeutics and PolyGene Sign Strategic Partnership – Joint Gene Therapy Delivery Push Targets NF1 Skin Disease